A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CBP-201 IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (CBP-201AU002)

Junying Wang1, Jeffery White2, Ken Sansone2, Lynda Speelman2, Rodney Sinclair3, Shawn Yang1, Wubin Pan1, Zheng Wei1

1Connect Biopharma, San Diego, CA, USA and Suzhou, China; 2Varicor Clinical Research Pty Ltd. Woolloongabba, Queensland, Australia; 3Suzhou Dermatology, East Melbourne, Australia

**RESULTS**

**Safety Results:**
- Several patients in the placebo group experienced TEAEs, while patients in the active group experienced different TEAEs.
- The most common TEAEs were headache, back pain, and injection site reactions.

**Efficacy Results:**
- Overall, efficacy assessments including total EASI score, IGA of severity of AD, BSA affected by AD, and quality of life as assessed by DLQI of AD at week 1, and showed improvement over time.

**Conclusion:**
- The results of this phase 1b study of CBP-201 in patients with moderate to severe AD, showed that multiple SC doses of CBP-201 studied showed rapid improvements in Quality of Life as assessed by DLQI at week 1, and this continued to improve out to week 4.

**DISCUSSION & CONCLUSIONS**

- Responses in investigator assessed (EASI) IGA 0-1, BSA and patient reported outcomes measured (P-MRS) generally showed a dose-dependent response and consistent improvements over baseline to week 4, with separation as early as week 1, primarily at higher doses of CBP-201 (150 mg and 300 mg) vs. placebo.
- All doses of CBP-201 studied showed rapid improvements in Quality of Life as assessed by DLQI at week 1, and this continued to improve out to week 4.

**Figure 3.** BSA, P-MRS and DLQI over time.

**Figure 2.** EASI Change from Baseline and IGA-0-1 over time.

**Table 2.** Treatment Emergent Adverse Events (Safety Population)

**Table 1.** Demographics of Study Participants

**Table 3.** Pharmacokinetics of CBP-201

**Figure 1.** Study Design

**Table 4.** Safety Review Committee Review: All global serious adverse events (SAE) and all other events leading to discontinuation from the study.

**Figure 2.** EASI Change from Baseline and IGA-0-1 over time.

**Figure 1.** Study Design

**Figure 2.** EASI Change from Baseline and IGA-0-1 over time.

**Table 3.** Pharmacokinetics of CBP-201

**Table 4.** Safety Review Committee Review: All global serious adverse events (SAE) and all other events leading to discontinuation from the study.